INTRODUCTION
Type 1 neurofibromatosis patients (NF1) have a significant predisposition to GISTs [1] . Ras activation through the somatic inactivation of the NF1 gene seems to be involved in the pathogenesis of NF1-associated GISTs [2] . Contrary to sporadic GISTs, the NF1-associated GISTs are characterized by a large number of small-sized tumors, typical location in the small intestine, and rare mutations of the KIT or PDGFRA [1] . However, occasional mutations of both the KIT and the PDGFRA have been reported in the NF1-associated GISTs, and the meaning of these mutations remains unclear [3] [4] [5] [6] . We present a case of NF1-associated GISTs with a missense point mutation of the KIT in a 52-year old woman.
CASE REPORT

Clinical summary
A 52-year-old woman with a history of NF1 presented with intermittent abdominal pain. She had been diagnosed as NF1 30 years ago and had a family history of NF1.
Her skin showed numerous café au lait spots and multiple cutaneous neurofibromas over the whole body. A physical examination demonstrated a 20 × 15 cm palpable mass in the left abdomen. The abdominal computed tomography revealed a 15 × 9 × 7 cm tumor and several smaller masses along the jejunal loop (Fig. 1) . On laparotomy, main tumor and numerous (more than 50) small nodular masses in the jejunum, located over 60 cm of the Treitz ligamen were found (Fig. 2) . Segmental resection of the jejunum was per- formed and the patient recovered uneventfully.
Pathologic findings
The largest tumor was 18 × 11 × 6 cm, showed mainly ex- 
DISCUSSION
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with characteristic morphologic, immunophenotypic and molecular features [7] . The gain of function KIT and PDGFRA mutations are considered to be a major driving force in the pathogenesis of sporadic, non-familial GISTs [8, 9] . Activating mutations in the KIT gene are pres- Additional somatic inactivation of the wild type NF1 allele in the ICCs seems to be the molecular event underlying the GIST development in the NF1 setting [2] . Because of these genetic disorders, patients with NF1 are estimated to develop GISTs at a rate of at least 45 times higher than sporadic cases and GISTs are considered as a type of the clinical symptoms seen in NF1.
Contrary to the sporadic GISTs, only occasional KIT and PDGFRA mutations have been reported in the NF1-associated GISTs. Ten KIT/PDGFRA mutations have been reported in the 87 investigated patients (Table 1) . Takazawa et al. [3] identified two KIT (e.g., Pro627Leu and Ile654Thr) and two PDGFRA (e.g., Pro589Lys and Arg822Ser) missense mutations in two separate tumors of each patient. Imatinib mesylate, a selective inhibitor of both KIT and PDGFRA, blocks these constitutively activated tyrosine kinases. This agent is currently being used as a molecular target drug for treating the GISTs and is showing a remarkable therapeutic effect on most of the GISTs [7] . Most of the NF1-associated GISTs lack the KIT and PDGFRA mutation, therefore imatinib mesylate is not expected to be effective on these multiple tumors. However, there was one report demonstrating the therapeutic effect of imatinib mesylate on the NF1-associated GIST with wild type KIT and PDGFRA [10] . 
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